Compounds > 1,2-bis(methylsulfonyl)-1-methylhydrazine
Page last updated: 2024-12-07

1,2-bis(methylsulfonyl)-1-methylhydrazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1,2-bis(methylsulfonyl)-1-methylhydrazine, often shortened to **BMSMH**, is a chemical compound with the formula **CH3NH(SO2CH3)2**. It's not as widely recognized as other research chemicals, and its importance lies mainly in its potential as a **precursor for the synthesis of other important compounds**, particularly those in the realm of pharmaceuticals and materials science.

Here's what we know about BMSMH and its potential:

**Properties:**

* **Solid at room temperature:** It's a white, crystalline solid.
* **Reacts with electrophiles:** This property makes it a useful building block for creating new molecules.
* **Can be modified:** The presence of sulfonyl groups (-SO2-) allows for further derivatization, leading to a wide range of potential applications.

**Research Applications:**

* **Synthesis of antitumor agents:** BMSMH has been explored as a starting material for the synthesis of novel anticancer drugs. The sulfonyl groups can be further modified to create compounds with specific biological activity.
* **Development of novel materials:** The potential to form strong bonds with other molecules makes BMSMH interesting for the development of new materials with unique properties, such as polymers or composites.
* **Exploration of reaction mechanisms:** BMSMH can be used as a model substrate for studying reactions involving sulfonyl groups and other functionalities, providing insights into the mechanism of these reactions.

**Limitations:**

* **Limited data available:** There is limited research published on BMSMH compared to other research chemicals.
* **Toxicity:** As with any new chemical, it's crucial to thoroughly investigate BMSMH's safety and toxicity profile before considering any practical applications.

**Overall, 1,2-bis(methylsulfonyl)-1-methylhydrazine (BMSMH) is a promising chemical for research due to its potential for synthesis of novel compounds with applications in various fields, including medicine, materials science, and reaction mechanism studies. However, further research is needed to fully explore its potential and address its limitations.**

Cross-References

ID SourceID
PubMed CID130630
CHEMBL ID66869
SCHEMBL ID4840036
MeSH IDM0192139

Synonyms (9)

Synonym
methanesulfonic acid, 2-methyl-2-(methylsulfonyl)hydrazide
110295-69-7
1,2-bis(methylsulfonyl)-1-methylhydrazine
bmsmh
CHEMBL66869
n'-methyl-n'-methylsulfonylmethanesulfonohydrazide
KYRBDGFWRYSMFS-UHFFFAOYSA-N
SCHEMBL4840036
DTXSID90149199
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID134252Mean life extension was determined in mice bearing Trypanosoma brucei gambiense (TxTAT 1.0), after administration of 0.2 mmol/kg per dose1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Methylating agents as trypanocides.
AID134254Mean life extension was determined in mice bearing Trypanosoma equiperdum (1559), after administration of 0.2 mmol/kg per dose1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Methylating agents as trypanocides.
AID733210Cytotoxicity against mouse AGT negative EMT6 cells under aerobic conditions after 4 to 24 hrs by clonogenic assay2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells.
AID121781Antitumor activity against L1210 leukemia cells in mice (activity expressed as average survival time of treated/control animals x 100)1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity.
AID134251Mean life extension was determined in mice bearing Trypanosoma brucei (M110) after administration of 0.2 mmol/kg per dose1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Methylating agents as trypanocides.
AID25380Half life measured at 30 degree Celsius relative to 37 degree Centigrade1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Studies on the mechanism of decomposition and structural factors affecting the aqueous stability of 1,2-bis(sulfonyl)-1-alkylhydrazines.
AID733208Cytotoxicity against human DU145 cells expressing AGT after 4 to 24 hrs by clonogenic assay2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells.
AID112133Antitumor activity against L1210 leukemia cells in mice, activity is expressed as optimal effective dose1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity.
AID99887Percentage of mice survived after 60 days of treatment with the compound was determined.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents.
AID134111Mean life extension in mice bearing Trypanosoma rhodesiense, after ip administration at a dose of 0.2 mmol/kg1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Methylating agents as trypanocides.
AID134255Mean life extension was determined in mice bearing Trypanosoma evansi (SAK), after administration of 0.2 mmol/kg per dose1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Methylating agents as trypanocides.
AID25381Half life measured by mean acidification in 1 mM potassium phosphate at pH 7.3-7.41994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Studies on the mechanism of decomposition and structural factors affecting the aqueous stability of 1,2-bis(sulfonyl)-1-alkylhydrazines.
AID121777Antitumor activity against B16 melanoma cells in mice, activity is expressed as average survival time of treated/control animals x 100.1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity.
AID124630Antitumor activity against L1210 leukemia cells in mice calculated as average change in body weight from onset to termination of therapy1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity.
AID112130Antitumor activity against B16 melanoma cells in mice, activity is expressed as optimal effective dose1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity.
AID134253Mean life extension was determined in mice bearing Trypanosoma brucei rhodesiense (YTAT 1.1) after administration of 0.2 mmol/kg per dose1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Methylating agents as trypanocides.
AID97314Evaluated for average percent change in body weight from onset to termination of therapy against L1210 Leukemia cells in mice after 40 mg/kg dose administration.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents.
AID134256Mean life extension was determined in mice bearing Trypanosoma evansi (SN) after administration of 0.2 mmol/kg per dose1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Methylating agents as trypanocides.
AID733206Half life in 1 mM potassium phosphate buffer at pH 7.4 at 50 uM by spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells.
AID100020Average survival time of treated group / control group x(100) was determined.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents.
AID124628Antitumor activity against mouse B16 melanoma cells, calculated as average change in body weight from onset to termination of therapy1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's3 (60.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
methyl methanesulfonate
[no description available]		1.9710methanesulfonate esteralkylating agent;
apoptosis inducer;
carcinogenic agent;
genotoxin;
mutagen
procarbazine
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.		1.9710benzamides;
hydrazines		antineoplastic agent
diethyl sulfate
diethyl sulfate: RN given refers to parent cpd; structure. diethyl sulfate : The diethyl ester of sulfuric acid.		1.9710alkyl sulfatealkylating agent;
apoptosis inducer;
carcinogenic agent;
mutagen
dimethyl sulfate
dimethyl sulfate: RN given refers to unlabeled cpd; structure. dimethyl sulfate : The dimethyl ester of sulfuric acid.		1.9710alkyl sulfatealkylating agent;
immunosuppressive agent
methylnitrosourea
Methylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-methyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by methyl and nitroso groups.		1.9710N-nitrosoureasalkylating agent;
carcinogenic agent;
mutagen;
teratogenic agent
streptozocin
[no description available]		1.9710
laromustine
laromustine: has antineoplastic activity		2.0810
1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine
1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine: a chloroethylating agent that alkylates and cross-links DNA; structure in first source		2.6930
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		1.9710dacarbazine
ConditionIndicatedRelationship StrengthStudiesTrials
Trypanosomiasis
Infection with protozoa of the genus TRYPANOSOMA.		01.9710
Leukemia L 1210
[description not available]		02.3720
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9710
Sarcoma 180
An experimental sarcoma of mice.		01.9710
African Sleeping Sickness
[description not available]		01.9710
Trypanosomiasis, African
A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.		01.9710
B16 Melanoma
[description not available]		01.9710